This article is more than 5 years old. Information may no longer be current.

Promising results found with prodrug for retinal diseases

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

WATERTOWN, Mass. — A prodrug has shown promising results for the treatment of wet age-related macular degeneration in an animal study, according to the drug’s developer.

OxiGene, based here, tested the compound Combretastatin A4 Prodrug in both transgenic mice with choroidal neovascularization caused by an overexpression of vascular endothelial growth factor and in mice with laser-induced rupture of Bruch’s membrane.

Both groups of mice had a “significant reduction” in CNV after daily intraperitoneal injections of the prodrug, according to a press release from OxiGene.

“Similar to the pigment epithelium-derived factor gene transfer, treatment with CA-4-P has potential for treatment of established CNV,” reported Peter Campochiaro, MD, and colleagues, in Investigative Ophthalmology and Visual Sciences.